Bio


Dr Natalia Medvedeva specializes in the treatment of infectious diseases. She has a special interest in antimicrobial stewardship and medical education.

Clinical Focus


  • Infectious Disease

Academic Appointments


Professional Education


  • Residency: Yale New Haven Dept of Internal Medicine (2020) CT
  • Board Certification: American Board of Internal Medicine, Infectious Disease (2022)
  • Board Certification, American Board of Internal Medicine, Infectious Diseases (2022)
  • Fellowship: Stanford University Infectious Disease Fellowships (2022) CA
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2020)
  • Medical Education: Georgetown University School of Medicine (2017) DC

All Publications


  • Validity of Coronavirus Disease 2019 International Classification of Diseases, Tenth Revision in the Urgent Care Setting and Impact on Antibiotic Prescribing Rates. Open forum infectious diseases Medvedeva, N., Ong'uti, S., Hersh, A. L., Chang, A., Mui, E., Stenehjem, E., Ha, D., Holubar, M. 2023; 10 (2): ofad010

    Abstract

    We validated  different coronavirus disease 2019 (COVID-19) International Classification of Diseases, Tenth Edition (ICD-10) encounter definitions across 2 urgent care clinics. Sensitivity of definitions varied throughout the pandemic. Inclusion of COVID-19 and COVID-19-like illness (CLI) ICD-10s rendered highest sensitivity but lowest specificity. Antibiotic prescribing rates were low for COVID-19 ICD-10 encounters, increasing with CLI ICD-10 encounters.

    View details for DOI 10.1093/ofid/ofad010

    View details for PubMedID 36751646

    View details for PubMedCentralID PMC9897297

  • The cascade of care in testing and treatment of latent tuberculosis infection in liver transplant candidates TRANSPLANT INFECTIOUS DISEASE Palacios, C., Medvedeva, N., Cheung, H., Cohen, E., Azar, M. M., Malinis, M. 2022: e13999

    Abstract

    Testing and treatment for latent tuberculosis infection (LTBI) can mitigate risk of active tuberculosis (TB) post-liver transplant (LT). Testing and treatment completion rates have been reported low in this population. Our study aims to quantify the proportion of LT candidates who completed LTBI care cascade in our center.A retrospective chart review was conducted on LT candidates from 2012 to 2021. Primary outcome was the proportion of patients who completed each cascade stage. Secondary outcome was an analysis of factors associated with positive and indeterminate LTBI testing.Of the 273 LT candidates, 265 (97.1%) were referred to transplant infectious disease (TID), 264 (96.7%) had orders for interferon-gamma release assay (IGRA), 262 (96%) underwent TID evaluation, and 259 (94.9%) completed IGRA. Twenty had LTBI, and 18 were treatment naïve and recommended for treatment. Of the 18, 15 (83.3%) agreed to therapy, 14 (77.8%) initiated treatment, and 12 (66.7%) completed treatment. No posttransplant TB reactivation occurred. Patients born in Asia, previous incarceration, past military service, and granuloma findings on chest imaging were likely to have positive IGRA (p < .05). Older age and travel to TB-endemic countries were likely to have indeterminate IGRA (p < .05). Indeterminate IGRAs were more common in QuantiFERON (QTF)-Gold Plus TB (15.3%) versus QTF-Gold TB (9.3%, p < .001).High rates of LTBI testing and treatment initiation and completion can be attributed to a standardized process that includes TID evaluation. Future studies in larger cohort are needed to better understand factors that can optimize the completion rates of LTBI treatment in LT candidates.

    View details for DOI 10.1111/tid.13999

    View details for Web of Science ID 000902047400001

    View details for PubMedID 36484433

  • Shorter durations of antibiotic therapy in organ transplant. Current opinion in organ transplantation Alegria, W., Medvedeva, N., Holubar, M. 2022; 27 (4): 257-262

    Abstract

    PURPOSE OF REVIEW: Recent evidence supports shorter courses of antibiotics for several common infections and prophylactic indications. Unfortunately, solid organ transplant patients are often underrepresented or excluded from these studies. As a result, prolonged antibiotic durations are often used in clinical practice despite a lack of demonstrable benefit. This paper reviews recent publications addressing antibiotic duration of therapy in SOT recipients.RECENT FINDINGS: Although largely limited to observational studies, longer courses of antibiotics for surgical prophylaxis, urinary tract infections, and bloodstream infections have not demonstrated benefit compared to shorter courses. In some instances, longer courses of therapy have been associated with harm (i.e., adverse drug events and development of resistance).SUMMARY: Although the data remains limited, findings from retrospective studies evaluating shorter courses of antibiotics in SOT patients is encouraging. More robust research is desperately needed to define the optimal duration of antibiotics for common infections in SOT patients.

    View details for DOI 10.1097/MOT.0000000000000996

    View details for PubMedID 36354251

  • Real-world assessment of the clinical utility of whole body 18F-FDG PET/CT in the diagnosis of infection. PloS one Medvedeva, N., Radcliffe, C., Malinis, M., Chen, M., Azar, M. M. 2022; 17 (11): e0277403

    Abstract

    Few studies have aimed to capture the full spectrum of 18fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) use for evaluation of infections in a real-world context. We performed a retrospective chart review of hospitalized patients who underwent 18F-FDG PET/CT for the workup of infection between April, 2013 and September, 2019. The clinical indications for and impact of 18F-FDG PET/CT on diagnostic and antimicrobial management were evaluated across different infectious indications. Sixty-one patients met the inclusion criteria. The most common indication was identifying a source of a known infection (46%), followed by fever of unknown etiology (FUE)/fever of unknown origin (FUO) (38%), and other (16%). 18F-FDG PET/CT was determined to have had a diagnostic or management clinical impact for a total of 22 patients (36%) including 12/28 (43%) of patients with known infection, 7/23 (30%) of patients with FUE/FUO, and 3/10 (30%) of patients with other indications. 18F-FDG PET/CT confirmed suspected prosthetic endovascular infection for 6/16 (38%) patients. In this study,18F-FDG PET/CT led to a clinical impact on diagnostic and treatment management of hospitalized patients across a variety of syndromes and particularly for source identification in the setting of known infection.

    View details for DOI 10.1371/journal.pone.0277403

    View details for PubMedID 36374789